

Psoriasis Drugs Market Size & Forecast by Therapeutic Class (Tumor Necrosis Factor-inhibitors, Interleukin-inhibitors, Vitamin D analogues), By Treatment (Topicals. Systemic, Biologics) And Trend Analysis from 2016 - 2022

<https://marketpublishers.com/r/P4F0D4D8991EN.html>

Date: October 2017

Pages: 171

Price: US\$ 4,450.00 (Single User License)

ID: P4F0D4D8991EN

Abstracts

The global psoriasis drugs market is expected to be valued at \$21.4 billion by 2022, as per a new report by Grand View Research, Inc. The increasing number of reimbursement policies for treatment, advanced diagnostic tools, raised disease awareness and improved technological systems are likely to increase the adoption of therapeutics.

Additionally, the rising prevalence and incidence of psoriasis is anticipated to fuel the market growth. The condition has neither exact causes nor treatments to cure. Certain environmental and genetic factors may trigger the disease onset. Most treatments for the condition target to decelerate the severity of the disease by stopping the keratinocyte hyperproliferation. The disease symptoms can be managed by following a healthy lifestyle.

Further key findings from the report suggest:

Tumor Necrosis Factor-inhibitors dominated the psoriasis therapeutic market in 2016 owing to its higher usage by healthcare practitioners and easy availability.

TNF-inhibitors are likely to lose market shares over the forecast period due to increasing adoption of IL-inhibitor therapy over conventional TNF-inhibitors

Interleukin-inhibitors sector is expected to grow at lucrative CAGR of 19.4% over

the forecast period because of improved safety and efficacy profiles of Interleukin-inhibiting drugs.

The U.S. market is the dominant region in the psoriasis therapeutic space. It led the market in terms of revenue with \$4.4 billion in 2016 due to the increasing number of patients seeking treatment and presence of well-established healthcare services.

In addition, presence of several key manufacturers in the U.S. and launch of novel drugs are some of the factors anticipated to increase the demand for therapeutics in this region

Japan is expected to be the fastest growing region over the next decade with lucrative CAGR of 13.0% from 2016 to 2022 due to growing awareness about the disease among the people. Furthermore, presence of a large target population and high unmet clinical needs are some of the factors expected to propel the growth of this region.

Some of the key players in this industry are AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, Eli Lilly & Company, AstraZeneca and Celgene Corporation.

Most of the key players are focusing on strategies such as expansion of their product portfolios and collaborations, mergers, & acquisitions. The emergence of biosimilars is a rising trend adopted by these companies.

Contents

CHAPTER 1 RESEARCH METHODOLOGY

- 1.1 Information procurement
- 1.2 Information or Data Analysis
 - 1.2.1 Market Formulation & Validation

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Disease Primer and Epidemiology
- 2.2 Global Market Overview
- 2.3 Product Pipeline
- 2.4 Competitive Landscape
- 2.5 Market Outlook
- 2.6 Market Snapshot

CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY

- 3.1 Disease Primer
 - 3.1.1 Types:
 - 3.1.1.1 Plaque Psoriasis
 - 3.1.1.2 Guttate Psoriasis
 - 3.1.1.3 Inverse Psoriasis
 - 3.1.1.4 Pustular Psoriasis
 - 3.1.1.5 Erythrodermic Psoriasis
 - 3.1.2 Pathophysiology
 - 3.1.3 Complications
- 3.2 Epidemiology by indications
- 3.3 Current prevalence rate and numbers for 7 major markets (U.S., Japan, 5 E.U.)
- 3.4 Current incidence rate and numbers for 7 major markets (U.S., Japan, 5 E.U.)
- 3.5 Forecast prevalence and incidence for 7 major markets (U.S., Japan, 5 E.U.)

CHAPTER 4 GLOBAL MARKET OVERVIEW

- 4.1 Introduction and Market Overview
 - 4.1.1 Market by Therapeutic Class
 - 4.1.1.1 Tumour Necrosis Factor Inhibitors
 - 4.1.1.1.1 Adalimumab

- 4.1.1.1.2 Infliximab
- 4.1.1.1.3 Etanercept
- 4.1.1.2 Interleukin-Inhibitors
 - 4.1.1.2.1 Ustekinumab
 - 4.1.1.2.2 Secukinumab
 - 4.1.1.2.3 Ixekizumab
 - 4.1.1.2.4 Brodalumab
- 4.1.1.3 Vitamin D analogues
 - 4.1.1.3.1 Calcitriol
 - 4.1.1.3.2 Calcipotriol
 - 4.1.1.3.3 Tacalcitol
- 4.1.1.4 Others
- 4.1.2 Market by Treatment
 - 4.1.2.1 Topicals
 - 4.1.2.1.1 Over-the-counter (OTC) Topicals
 - 4.1.2.1.2 Topical non-steroids
 - 4.1.2.1.3 Topical Steroids
 - 4.1.2.2 Systemic
 - 4.1.2.2.1 Retinoid
 - 4.1.2.2.2 Cyclosporine
 - 4.1.2.2.3 Methotrexate
 - 4.1.2.3 Biologics
 - 4.1.2.3.1 Tumour necrosis factor alpha (TNF-?) inhibitors
 - 4.1.2.3.2 Interleukin 12 and 23 (IL-12/23) inhibitors
 - 4.1.2.3.3 Interleukin 17 (IL-17) inhibitor
 - 4.1.2.3.4 T cell inhibitor
- 4.1.3 Market size & Forecast
- 4.1.4 Sales Performance
- 4.1.5 Market Share Distribution
- 4.1.6 Major Product Overview
 - 4.1.6.1 Humira
 - 4.1.6.2 Remicade
 - 4.1.6.3 Enbrel
 - 4.1.6.4 Stelara
 - 4.1.6.5 Cosentyx
 - 4.1.6.6 Taltz
 - 4.1.6.7 Otezla
- 4.1.7 Market Dynamics among Leading Brands
- 4.2 Patent Expiry Analysis

- 4.3 Drivers and Challenges
- 4.4 M&A, Deal Landscape (2013-2017 YTD)
- 4.5 Pricing and Reimbursement Environment
- 4.6 Biosimilar Evolution (India, China, South Korea)
 - 4.6.1 India
 - 4.6.2 China
 - 4.6.3 South Korea
- 4.7 Emerging Markets
- 4.8 SWOT Analysis

CHAPTER 5 PRODUCT PIPELINE

- 5.1 Pipeline Landscape
 - 5.1.1 Leading drugs in development
 - 5.1.1.1 Mode of Approach: Injectables
 - 5.1.1.2 Mode of Approach: Oral
 - 5.1.1.3 Mode of Approach: Topical
 - 5.1.1.4 Mode of Approach: Biosimilar
 - 5.1.2 Key R&D Trends
- 5.2 Promising Drug Candidates in Pipeline
 - 5.2.1 Late Stage Pipeline and Sales Forecast
 - 5.2.2 Profile of disruptive drugs
 - 5.2.2.1 GP2015 (Erelzi)
 - 5.2.2.2 GP2017
 - 5.2.2.3 ABP501 (Amjevita)
 - 5.2.2.4 BI 655066
 - 5.2.2.5 Cimzia
 - 5.2.2.6 Tildrakizumab
 - 5.2.2.7 BI695501

CHAPTER 6 COMPETITIVE LANDSCAPE

- 6.1 AbbVie Inc.
 - 6.1.1 Company overview
 - 6.1.2 Current Product Portfolio
 - 6.1.3 Product Forecast Sales up to 2022
 - 6.1.4 Strategic initiatives(Humira)
 - 6.1.5 Company - Key News Flow
 - 6.1.6 Pipeline View

- 6.1.7 Pipeline Forecast
- 6.1.8 Catalysts and Event Calendar
- 6.1.9 SWOT Analysis
- 6.2 Amgen, Inc.
 - 6.2.1 Company overview
 - 6.2.2 Current Product Portfolio
 - 6.2.3 Product Forecast Sales up to 2022
 - 6.2.4 Strategic initiatives(Enbrel)
 - 6.2.5 Company - Key News Flow
 - 6.2.6 Pipeline View
 - 6.2.7 Pipeline Forecast
 - 6.2.8 Catalysts and Event Calendar
 - 6.2.9 SWOT Analysis
- 6.3 Johnson & Johnson
 - 6.3.1 Company overview
 - 6.3.2 Current Product Portfolio
 - 6.3.3 Product Forecast Sales up to 2022
 - 6.3.4 Strategic initiatives
 - 6.3.4.1 Remicade
 - 6.3.4.2 Stelara
 - 6.3.4.3 Tremfya
 - 6.3.5 Company - Key News Flow
 - 6.3.6 Pipeline View
 - 6.3.7 Pipeline Forecast
 - 6.3.8 Catalysts and Event Calendar
 - 6.3.9 SWOT Analysis
- 6.4 Novartis AG
 - 6.4.1 Company overview
 - 6.4.2 Current Product Portfolio
 - 6.4.3 Product Forecast Sales up to 2022
 - 6.4.4 Strategic initiatives(Cosentyx)
 - 6.4.5 Company - Key News Flow
 - 6.4.6 Pipeline View
 - 6.4.7 Pipeline Forecast
 - 6.4.8 Catalysts and Event Calendar
 - 6.4.9 SWOT Analysis
- 6.5 Eli Lilly and Company
 - 6.5.1 Company overview
 - 6.5.2 Current Product Portfolio

- 6.5.3 Product Forecast Sales up to 2022
- 6.5.4 Strategic initiatives(Taltz)
- 6.5.5 Company - Key News Flow
- 6.5.6 Pipeline View
- 6.5.7 Pipeline Forecast
- 6.5.8 Catalysts and Event Calendar
- 6.5.9 SWOT Analysis
- 6.6 AstraZeneca
 - 6.6.1 Company overview
 - 6.6.2 Current Product Portfolio
 - 6.6.3 Strategic initiatives(Siliq)
 - 6.6.4 Company - Key News Flow
 - 6.6.5 Pipeline View
 - 6.6.6 Pipeline Forecast
 - 6.6.7 Catalysts and Event Calendar
 - 6.6.8 SWOT Analysis
- 6.7 Celgene Corporation
 - 6.7.1 Company overview
 - 6.7.2 Current Product Portfolio
 - 6.7.3 Product Forecast Sales up to 2022
 - 6.7.4 Strategic initiatives(Otezla)
 - 6.7.5 Company - Key News Flow
 - 6.7.6 Pipeline View
 - 6.7.7 Pipeline Forecast
 - 6.7.8 Catalysts and Event Calendar
 - 6.7.9 SWOT Analysis

CHAPTER 7 MARKET OUTLOOK

- 7.1 What the future holds
- 7.2 Winners and Losers
- 7.3 Emerging Companies
- 7.4 The road ahead

List Of Tables

LIST OF TABLES

TABLE 1 Current prevalence rates and numbers across 7 major markets - 2016

TABLE 2 Current incidence rates and numbers across 7 major markets - 2016

TABLE 3 Forecast global prevalence 2016 - 2022

TABLE 4 Forecast global incidence 2016 - 2022

TABLE 5 Forecast prevalence for 7 major markets 2016 - 2022

TABLE 6 Forecast incidence for 7 major markets 2016 - 2022

TABLE 7 Psoriasis therapeutics market size and forecast

TABLE 8 Geographic sales performance of psoriasis therapeutics by region

TABLE 9 Psoriasis therapeutic market by drug class

TABLE 10 Forecast sales of leading brands in the global psoriasis market

TABLE 11 Global psoriasis pipeline forecast

TABLE 12 Global psoriasis pipeline sales forecast

TABLE 13 Psoriasis sales forecast by company

TABLE 14 Psoriasis therapeutic market share by company

TABLE 15 Patent Expiry Analysis

TABLE 16 M&A, Deal Landscape

TABLE 17 Mode of Approach: Injectables

TABLE 18 Mode of Approach: Oral

TABLE 19 Mode of Approach: Topical

TABLE 20 Mode of Approach: Biosimilar

TABLE 21 Late-stage pipeline and sales forecast

TABLE 22 Product Profile: GP2015 (Erelzi)

TABLE 23 Product Profile: GP2017

TABLE 24 Product Profile: ABP501 (Amjevita)

TABLE 25 Product Profile: BI655066

TABLE 26 Product Profile: Cimzia

TABLE 27 Product Profile: Tildrakizumab

TABLE 28 Product Profile: BI695501

TABLE 29 Product Portfolio: Humira

TABLE 30 Humira forecast sales up to 2022

TABLE 31 AbbVie pipeline view

TABLE 32 AbbVie catalysts and event calendar

TABLE 33 Product Portfolio: Enbrel

TABLE 34 Enbrel forecast sales up to 2022

TABLE 35 Amgen pipeline view

TABLE 36	Amgen catalysts and event calendar
TABLE 37	Product Portfolio: Remicade
TABLE 38	Product Portfolio: Stelara
TABLE 39	Product Portfolio: Tremfya
TABLE 40	Remicade product forecast sales upto 2022
TABLE 41	Stelara product forecast sales upto 2022
TABLE 42	Tremfya product forecast sales upto 2022
TABLE 43	Johnson & Johnson pipeline view
TABLE 44	Johnson & Johnson catalysts and event calendar
TABLE 45	Product Portfolio: Cosentyx
TABLE 46	Cosentyx product forecast sales upto 2022
TABLE 47	Novartis pipeline view
TABLE 48	Novartis catalysts and event calendar
TABLE 49	Product Portfolio: Taltz
TABLE 50	Taltz forecast sales up to 2022
TABLE 51	Eli Lilly pipeline view
TABLE 52	Eli Lilly catalysts and event calendar
TABLE 53	Product Portfolio: Siliq
TABLE 54	AstraZeneca pipeline view
TABLE 55	AstraZeneca catalysts and event calendar
TABLE 56	Product Portfolio: Otezla
TABLE 57	Otezla forecast sales up to 2022
TABLE 58	Celgene pipeline view
TABLE 59	Celgene catalysts and event calendar

List Of Figures

LIST OF FIGURES

- FIG. 1 Market research process
- FIG. 2 Information Procurement
- FIG. 3 Primary research pattern
- FIG. 4 Market research approaches
- FIG. 5 Value chain based sizing & forecasting
- FIG. 6 QFD modelling for market share assessment
- FIG. 7 Market summary, 2016
- FIG. 8 Current prevalence rates and numbers across 7 major markets - 2016
- FIG. 9 Current incidence rates and numbers across 7 major markets - 2016
- FIG. 10 Global psoriasis epidemiology 2016 - 2022
- FIG. 11 Market segmentation & scope
- FIG. 12 Psoriasis therapeutic market by drug class
- FIG. 13 Psoriasis market share by company 2016 - 2022
- FIG. 14 Market trends & outlook
- FIG. 15 Market driver relevance analysis (Current & future impact)
- FIG. 16 Market restraint relevance analysis (Current & future impact)
- FIG. 17 SWOT Analysis (Psoriasis therapeutic sector)
- FIG. 18 SWOT Analysis (AbbVie)
- FIG. 19 SWOT Analysis (Amgen)
- FIG. 20 SWOT Analysis (Johnson & Johnson)
- FIG. 21 SWOT Analysis (Novartis)
- FIG. 22 SWOT Analysis (Eli Lilly)
- FIG. 23 SWOT Analysis (AstraZeneca)
- FIG. 24 SWOT Analysis (Celgene)

I would like to order

Product name: Psoriasis Drugs Market Size & Forecast by Therapeutic Class (Tumor Necrosis Factor-inhibitors, Interleukin-inhibitors, Vitamin D analogues), By Treatment (Topicals. Systemic, Biologics) And Trend Analysis from 2016 - 2022

Product link: <https://marketpublishers.com/r/P4F0D4D8991EN.html>

Price: US\$ 4,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P4F0D4D8991EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970